Euroscreen Achieves Milestone in CNS Therapeutic Partnership with Cephalon

Share Article

Euroscreen announced that it has completed its five-year target discovery and screening collaboration with Cephalon, Inc.. In the final, two year phase of the collaboration, Euroscreen delivered optimized lead molecules on a non-disclosed, specific GPCR target triggering a milestone payment by Cephalon.

Euroscreen announced that it has completed its five-year target discovery and screening collaboration with Cephalon, Inc.. In the final, two year phase of the collaboration, Euroscreen delivered optimized lead molecules on a non-disclosed, specific GPCR target triggering a milestone payment by Cephalon. Financial details were not disclosed.

"We are pleased that the Euroscreen collaboration has reached the compound optimization stage with deliverables that expand our preclinical drug discovery portfolio," said Michael Williams, VP, WW Discovery Research at Cephalon.

"The achievement of this milestone validates our lead optimization strategy and is consistent with Euroscreen's evolution as a drug discovery company. We are proud to have delivered multiple, patentable, drug-like chemical series to Cephalon " said Jean Combalbert, CEO of Euroscreen. "We believe these compounds will have the ability to effectively compete with other compounds targeting the same GPCR and will advance drug discovery in the area".

For further information, please contact:
Euroscreen S.A.
Tel: +32 71 348 500

Jean Combalbert, Ph.D.        Al Gray, Ph.D.
Chief Executive Officer        Director, Business Development

About Euroscreen S.A.
Euroscreen, a privately held company based in Brussels, Belgium, is a preclinical-stage biopharmaceutical company focusing on the discovery, development and partnering of small molecule drugs for unmet medical needs. Euroscreen is developing a pipeline of compounds targeting G Protein-Coupled Receptors (GPCRs) using over 15 years of experience in research and commercialization of this critical class of drug targets.

Euroscreen is now in preclinical development with internal drug candidates for GPR43, a proprietary GPCR implicated in metabolic and inflammatory disorders. The Company is also advancing several other early, preclinical GPCR programs.

The Company developed a broad target patent portfolio for licensing to biopharmaceutical companies. Such patents address GPCRs such as CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2 for type II diabetes. Euroscreen is able to offer intellectual property rights to companies for the development of therapeutic drugs that act through these targets.

Euroscreen pursues a dual platform strategy to combine its internal drug discovery programs with its custom screening business unit (Euroscreen FAST), to provide GPCR customized screening and other services for biotech and pharmaceutical companies around the world. The Company has ongoing research and licensing partnerships with AstraZeneca, Boehringer Ingelheim, BMS Company, Cephalon, Grunenthal, HGS, Monogram Biosciences, Novartis and Pfizer.
(http://www.euroscreen.com)

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

ALFRED GRAY
Visit website